Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The Influences of Caffeine on Heart Rate Variability of Preterm Infants

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified January 2013 by Rambam Health Care Campus
Sponsor:
Information provided by (Responsible Party):
wamir, Rambam Health Care Campus
ClinicalTrials.gov Identifier:
NCT01769118
First received: January 14, 2013
Last updated: January 15, 2013
Last verified: January 2013
  Purpose

Caffeine has a stimulatory effect on the ANS. This has not yet been investigated in preterm infant who get caffeine before stopping ventilation. The investigators hypothesis is that this stimulatory effect may be characterized by HRV analysis methods.


Condition Intervention
Autonomic Nervous System
Drug: Caffeine

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: The Influences of Caffeine on HRV of Preterm Infants

Resource links provided by NLM:


Further study details as provided by Rambam Health Care Campus:

Primary Outcome Measures:
  • Heart rate variability [ Time Frame: 1 hour ] [ Designated as safety issue: No ]
    Heart rate, SD, SDNN, HF, LF, VLF, TP


Estimated Enrollment: 25
Study Start Date: January 2013
Estimated Study Completion Date: March 2014
Estimated Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Caffeine
caffeine will be given according to clinical judgment
Drug: Caffeine
Caffeine will be given according to departmental protocol
Other Name: caffeine

  Eligibility

Ages Eligible for Study:   25 Weeks to 34 Weeks
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

25 preterm infants

Criteria

Inclusion Criteria:

  • infants born before 34 weeks gestation

Exclusion Criteria:

  • sepsis
  • congenital malformations
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01769118

Contacts
Contact: Amir Weissman, MD 0502061366 ext 972 wamir@rambam.health.gov.il
Contact: Irena Olanovsky, MD 0502064799972

Locations
Israel
RMC Not yet recruiting
Haifa, Israel
Contact: Amir Weissman, MD    0502061366 ext 972    wamir@rambam.health.gov.il   
Principal Investigator: Amir Weissman, MD         
Sub-Investigator: Irena Olanovsky, MD         
Sponsors and Collaborators
Rambam Health Care Campus
  More Information

No publications provided

Responsible Party: wamir, Dr., Rambam Health Care Campus
ClinicalTrials.gov Identifier: NCT01769118     History of Changes
Other Study ID Numbers: 0442-12
Study First Received: January 14, 2013
Last Updated: January 15, 2013
Health Authority: Israel: Ministry of Health

Keywords provided by Rambam Health Care Campus:
Autonomic nervous system

Additional relevant MeSH terms:
Caffeine
Central Nervous System Agents
Central Nervous System Stimulants
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Phosphodiesterase Inhibitors
Physiological Effects of Drugs
Purinergic Agents
Purinergic Antagonists
Purinergic P1 Receptor Antagonists
Therapeutic Uses

ClinicalTrials.gov processed this record on November 27, 2014